TD Cowen Maintains Outperform on Sage Therapeutics, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral maintains an Outperform rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $105 to $28.
August 08, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TD Cowen analyst maintains Outperform rating on SAGE but lowers price target from $105 to $28.
The lowering of the price target by TD Cowen from $105 to $28 indicates a significant decrease in the expected value of SAGE. This could lead to a negative sentiment among investors, potentially causing a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100